Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00131300 | A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis | PHASE3 | COMPLETED | - | — | — | Apr 1, 2004 | Feb 1, 2006 | Mar 18, 2015 | 6 | France, Germany |
| NCT00131768 | A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle Osteoarthritis | PHASE3 | COMPLETED | - | — | — | Nov 1, 2003 | Feb 1, 2006 | Mar 18, 2015 | 5 | Germany, Italy +1 |
| NCT00949494 | Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA) | PHASE1 | COMPLETED | 30 | — | — | Sep 1, 2006 | Feb 1, 2009 | Sep 10, 2019 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| Synvisc | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Synvisc (hylan G-F 20) | DEVICE | - |
| Synvisc | DEVICE | intra-articular, 3 weekly injections |
Inclusion Criteria: * Patients with symptomatic OA pain of shoulder (gleno-humeral) Exclusion Criteria: * Patients with current or prior conditions or treatment that would impede measurement of efficacy or safety